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Introduction
Alpha-1 antitrypsin (AAT) belongs to the superfamily of serine protease inhibitors (SERPINs) and is an import-
ant regulator of neutrophil elastase (NE) and cathepsin G (1, 2). Humans and mice have high serum levels of  
AAT, ranging at 1–2 mg/mL in humans and 3–4 mg/mL in mice, which increase upon injury or infection, 
thus underlining the (patho-) physiological need for sustained antiproteolytic activity in both species (1, 3, 4).
AAT is encoded by the SERPINA1 gene and mainly produced by hepatocytes but also by monocytes/mac-
rophages and lung epithelial cells (5–7). Over 150 mutations have been identified in the SERPINA1 gene, some 
of which affect the concentration and/or functionality of AAT protein. The S (Glu264Val) and Z (Glu342Lys) 
mutations are most common and clinically significant and are both known to cause AAT deficiency (AATD) 
(2, 5, 8–11). Individuals homozygous for the Z allele exhibit roughly 90% reduced levels of circulating AAT 
and have an increased risk of developing chronic obstructive pulmonary disease (COPD) with emphysema 
(12–15). Many patients with AATD are lifelong treated with AAT augmentation therapy (16). There is clinical 
evidence that therapy with weekly infusions of AAT decreases emphysema progression (17, 18).
Current recommendations for AAT augmentation therapy are not based on randomized clinical trials 
but rather are oriented at serum AAT levels. Therefore, the standard augmentation therapy recommended 
for patients with AATD is defined as 60 mg AAT/kg body weight (b.w.) per week reaching approximately 
50% of  serum AAT levels found in healthy individuals (19). Many patients with AATD under standard 
augmentation therapy still experience emphysema progression. A recent prospective study revealed that 
double-dose augmentation therapy of  120 mg AAT/kg b.w. per week increased AAT levels to normal and 
reduced serine protease activities and hence markers of  elastin degradation in bronchoalveolar lavage 
(BAL) fluids of  patients with AATD (19). Results from such double-dose augmentation therapies suggest 
that current single-dose augmentation therapies may underestimate the need for AAT bioavailability in 
patients with AATD, thus calling for individualized AAT dosing considerations (19).
Alpha-1 antitrypsin (AAT) is a major inhibitor of serine proteases in mammals. Therefore, its 
deficiency leads to protease–antiprotease imbalance and a risk for developing lung emphysema. 
Although therapy with human plasma-purified AAT attenuates AAT deficiency–related 
emphysema, its impact on lung antibacterial immunity is poorly defined. Here, we examined the 
effect of AAT therapy on lung protective immunity in AAT-deficient (KO) mice challenged with 
Streptococcus pneumoniae. AAT-KO mice were highly susceptible to S. pneumoniae, as determined 
by severe lobar pneumonia and early mortality. Mechanistically, we found that neutrophil-derived 
elastase (NE) degraded the opsonophagocytically important collectins, surfactant protein A 
(SP-A) and D (SP-D), which was accompanied by significantly impaired lung bacterial clearance in 
S. pneumoniae–infected AAT-KO mice. Treatment of S. pneumoniae–infected AAT-KO mice with 
human AAT protected SP-A and SP-D from NE-mediated degradation and corrected the pulmonary 
pathology observed in these mice. Likewise, treatment with Sivelestat, a specific inhibitor of 
NE, also protected collectins from degradation and significantly decreased bacterial loads in S. 
pneumoniae–infected AAT-KO mice. Our findings show that NE is responsible for the degradation  
of lung SP-A and SP-D in AAT-KO mice affecting lung protective immunity in AAT deficiency.
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Since AAT deficiency is a susceptibility factor for lung damage during bacterial exacerbations (20–23), 
it is equally important to understand how lung protective immunity against bacterial challenge is influenced 
by the levels of  AAT. Therefore, we examined the effect of  AAT deficiency on lung protective immunity 
against Streptococcus pneumoniae in mice in the absence or presence of  augmentation therapy.
Results
Endogenous AAT levels decrease in serum and increase in lungs in response to S. pneumoniae infection of  mice. 
In initial experiments, we examined the effect of  pneumococcal challenge on endogenous AAT levels 
in WT mice. Under baseline conditions, mice showed AAT serum levels of  3–4 mg/mL, consistent 
with previous reports (Figure 1A) (3, 4, 24). Relative to mock infection, S. pneumoniae–challenged mice 
demonstrated approximately 25% decreased serum AAT levels on days 2–4 postinfection. At the same 
time, we observed significantly increased AAT levels in BAL fluid (BALF) of  WT mice challenged with 
S. pneumoniae on days 1–4 postinfection (Figure 1B).
Effect of  AATD on lung antibacterial immunity. The results from the WT mice showed that lung 
challenge with S. pneumoniae triggered a decrease in systemic AAT levels while pulmonary AAT lev-
els increased in response to infection. We next examined whether AAT interferes with pneumococcal 
growth in vitro. However, growth of  S. pneumoniae was not affected by 1–2.5 mg/mL of  human AAT 
(hAAT) within 4 hours (Supplemental Figure 1; supplemental material available online with this article; 
https://doi.org/10.1172/jci.insight.140816DS1). Even 5 mg of  hAAT/mL did not affect pneumococcal 
growth in vitro compared to controls (data not shown).
Next, to reflect the clinical situation of  inherited AATD, we employed recently generated AAT-KO 
mice lacking all 5 mouse serpin A1 paralogues, thus leading to complete AAT protein absence. AAT-
KO mice were used at the age of  8–14 weeks while spontaneously developing lung emphysema only at 
advanced age of  more than 35 weeks (25). As shown in Figure 2, AAT-KO mice responded to S. pneu-
moniae infection with significantly increased bacterial loads in BALF and lung tissue (Figure 2, B and 
C). Consistent with these findings, survival of  AAT-KO mice was significantly decreased (by 50%) when 
compared with S. pneumoniae–infected WT mice (Figure 2D). Microscopic inspection of  lungs revealed 
lobar pneumonia in S. pneumoniae–infected AAT-KO mice but not in WT mice (Figure 2, E and I). H&E-
stained lung tissue sections of  untreated WT and AAT-KO mice revealed a normal lung architecture with 
unaffected bronchi and bronchioles in both experimental groups (Figure 2, F and J); however, only the S. 
pneumoniae–infected AAT-KO mice showed severe lobar pneumonia characterized by massive interstitial 
and alveolar infiltration of  neutrophils together with interstitial and alveolar edema and alveolar hemor-
rhage (Figure 2, G and H, K and L). As a marker of  lung injury, we determined desmosine contents in BAL 
fluids of  WT and AAT-KO mice at baseline and on days 1 and 2 postinfection. Desmosine is an amino acid 
of  elastin and therefore reflects a biomarker for elastin degradation (26). Under baseline conditions (CL in 
Figure 2M), we found significantly higher desmosine levels in BALF of  AAT-KO mice compared with WT 
mice. We also found substantially increased desmosine levels in BALF of  S. pneumoniae–infected AAT-KO 
mice as compared with WT mice on day 2 postinfection. In parallel, AAT-KO mice revealed significantly 
increased neutrophil counts in BALF and lung tissue on day 3 postinfection (Supplemental Figure 2). No 
significant differences in numbers of  alveolar macrophages and exudate macrophages were observed in 
WT versus AAT-KO mice after S. pneumoniae infection (data not shown).
Effect of  AAT augmentation therapy on lung antibacterial immunity in AAT-KO mice. Based on the finding 
that S. pneumoniae infection of  AAT-KO mice led to substantially increased lung bacterial loads along 
with significantly decreased survival, we next aimed to reverse the phenotype in the KO mice by systemic 
treatment of  mice with hAAT. As shown in Supplemental Figure 3, hAAT was detectable by Western 
blot analysis in plasma and BALF of  AAT-KO mice receiving AAT therapy at 48–72 hours postinfection 
(lanes 5–8) but not in AAT-KO mice receiving PBS as vehicle (lanes 1–4). Human AAT protein levels 
increased on days 2 and 3 postinfection both in plasma and in BALF of  S. pneumoniae–infected AAT-KO 
mice receiving AAT therapy with a slight decline of  AAT levels by day 3 (Supplemental Figure 3F).
Based on the observation that AAT-KO mice were highly susceptible to pneumococcal pneumonia, we 
questioned what effect hAAT therapy would have on lung protective immunity in AAT-KO mice against 
S. pneumoniae. As shown in Figure 3, AAT-KO mice demonstrated a significantly improved bacterial clear-
ance on days 2–3 postinfection after initiation of  hAAT therapy, whereas bacterial outgrowth was observed 
in PBS-treated AAT-KO mice infected with S. pneumoniae (Figure 3, B and C). In line, AAT-KO mice 
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receiving hAAT therapy had significantly improved survival of  pneumococcal pneumonia compared with 
PBS-treated, S. pneumoniae–infected AAT-KO mice (Figure 3D). As expected, histopathology of  lungs 
from PBS-treated, S. pneumoniae–infected AAT-KO mice revealed severe pneumococcal pneumonia, while 
lungs of  S. pneumoniae–challenged AAT-KO mice treated with hAAT demonstrated substantially less severe 
interstitial and alveolar inflammation (Figure 3E).
We next examined the effect of  hAAT therapy on total proteolytic and NE activity in BALF and BAL 
neutrophils of  S. pneumoniae–infected mice of  the 2 treatment groups. Using gelatin-based zymography 
(Figure 3F), we observed substantial proteolytic (i.e., gelatinolytic) activity in BALF of  S. pneumoniae–
infected AAT-KO mice (illustrated by white proteolysis bands in lanes 2–4), which was drastically blocked 
by the therapy with hAAT (lanes 5–7), and only partially blocked by oxidized AAT, which is known to be 
devoid of  NE-inhibitory activity (27, 28) (lanes 8–10). In selected experiments, we also examined the effect 
of  AAT therapy on BAL NE activity in mice. Baseline NE activity was observed in peripheral neutrophils 
from untreated WT and AAT-KO mice serving as controls (Figure 3G). Of  note, BAL neutrophils of  S. 
pneumoniae–challenged AAT-KO mice treated with hAAT showed significantly lower NE activity com-
pared with S. pneumoniae–infected, PBS-treated AAT-KO mice, thus illustrating a link between systemic 
therapy with hAAT and inhibition of  NE activity in BAL neutrophils of  S. pneumoniae–challenged AAT-
KO mice (Figure 3G). NE is a highly potent serine protease that is able to degrade lung elastin fibers and 
to activate proinflammatory cytokines (12, 13, 29). In line with this, we found significantly reduced levels 
of  TNF-α, IL-1β, IL-6, CXCL1, and elastin-derived desmosine in BALF of  S. pneumoniae–infected AAT-
KO mice receiving therapy with hAAT (Figure 3, H–L). Notably, reported differences in outcome between 
groups were not due to differences in leukocyte subset recruitment (data not shown).
Augmentation therapy improves lung antibacterial immunity in AAT-KO mice via inhibition of  NE. To exclude 
potential immunomodulatory properties of  hAAT therapy underlying the observed effects in S. pneumoniae–
infected AAT-KO mice, we treated AAT-KO mice with oxidized or native hAAT followed by infection with S. 
pneumoniae. Of note, oxidation of  the methionine residues of  AAT substantially decreases its ability to inhibit 
various proteases, including the serine protease NE, while preserving its immunomodulatory activity (27, 28). 
AAT-KO mice augmented with hAAT demonstrated significantly improved bacterial clearance in BALF and 
lung tissue on day 2 postinfection, while no significant effect was observed in AAT-KO mice treated with oxi-
dized hAAT (Figure 4, A and B). In additional experiments, S. pneumoniae–challenged NE-KO mice treated 
with vehicle or hAAT had similar CFU counts in their lungs (Figure 4, C and D). No significant differences 
in BALF cytokines were noted between groups (Figure 4, E–L). Thus, therapy with hAAT appears to improve 
lung protective immunity primarily by inhibition of  proteolysis, specifically the activity of  NE.
Effect of  AAT deficiency on bacterial phagocytosis, killing, and burst induction in professional phagocytes. 
Based on the observation that hAAT-augmented AAT-KO mice coped better with pneumococcal chal-
lenge compared with vehicle-treated, S. pneumoniae–infected AAT-KO mice, we examined bacterial 
Figure 1. AAT protein levels in plasma and BAL fluids of WT mice infected with S. pneumoniae. WT mice were left untreated (black bars), were mock-infected 
with PBS (white bars), or were infected with S. pneumoniae (gray bars). Endogenous AAT protein was measured in plasma (A) and BAL fluids (B) of mice at days 
1, 2, 3, and 4 postinfection by ELISA. Data are shown as mean ± SD of n = 7–9 mice per time point and treatment group and are representative of 2 independent-
ly performed experiments. *P ≤ 0.05, ***P ≤ 0.001, ****P ≤ 0.0001 compared with mock-infected mice (Mann-Whitney U test). Spn, S. pneumoniae.
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phagocytosis, killing, and burst induction in professional phagocytes of  WT and AAT-KO mice in the 
absence or presence of  hAAT. As shown in Figure 5, A–D, no differences in pneumococcal phagocytosis 
and killing were observed between rAMs or BM-PMNs of  WT or AAT-KO mice, in either the absence 
or presence of  hAAT. Moreover, BM-PMNs of  WT and AAT-KO mice responded similarly to S. pneu-
moniae– or zymosan-induced respiratory burst (Figure 5, E and F). These data illustrate that differences 
in antibacterial responses between WT and AAT-KO mice are not due to differences in pneumococcal 
phagocytosis and killing by the respective professional phagocyte subsets.
Human AAT remains biologically active in S. pneumoniae–infected AAT-KO mice. In the next set of  experiments, 
we wished to determine whether hAAT employed in the current study would retain NE complex–forming 
Figure 2. Effect of AAT deficiency on outcome in pneumococcal pneumonia. WT mice (white bars) and AAT-KO mice (gray bars) were infected orotracheally 
with S. pneumoniae and were analyzed at the indicated time points, as shown (A). (B and C) Bacterial loads in BALF (B) and lung tissue (C) at 24 hours and 48 
hours postinfection. Values are shown as mean ± SD (n = 6–9 mice per time point and treatment group) and are representative of 2 independent experiments. 
(D) Survival analysis of S. pneumoniae–infected WT and AAT-KO mice (n = 9 mice per group). (E and I) Photographic illustration of lungs from S. pneumoniae–
infected WT and AAT-KO mice at day 3 postinfection. (F–L) Lung histopathology of untreated (F and J, scale bars: 500 μm), or S. pneumoniae–infected WT (G, 
scale bar: 1 mm; H scale bar: 50 μm) or AAT-KO mice (K, scale bar: 1 mm; L, scale bar: 50 μm). Illustrations in E–L are representative of n = 4 mice per group. (M) 
Desmosine levels in BALF of untreated (CL) or S. pneumoniae–infected WT or AAT-KO mice, as indicated. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 compared with 
untreated or S. pneumoniae–infected WT mice, +++P ≤ 0.001 compared with day 2 (Mann-Whitney U test, log-rank test).
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Figure 3. Effect of AAT augmentation therapy on outcome in S. pneumoniae–infected AAT-KO mice. (A) Experimental setup. AAT-KO mice were treated with 
Respreeza (gray bars) or vehicle i.p. (white bars), as indicated. (B and C) Bacterial load in BALF (B) and lung tissue (C) at 48 hours and 72 hours postinfection. Data 
are shown as mean ± SD of n = 5–8 mice per time point and group. (D) Survival of AAT as compared with vehicle-treated, S. pneumoniae–infected AAT-KO mice (n 
= 9 mice per group). (E) Lung histopathology of S. pneumoniae–infected AAT-KO mice after PBS (upper illustration) or hAAT augmentation therapy as outlined in A 
(lower illustration in E). The data are representative of n = 5 mice per group. Original magnification, x10. (F) Proteolytic activity in BALF of S. pneumoniae–infected 
AAT-KO mice receiving PBS or native or oxidized AAT. The data are representative of n = 5–6 mice per group. M, marker (gel without loaded sample). (G) NE activity 
in BAL neutrophils at day 1 postinfection. Bone marrow–derived neutrophils from untreated WT or AAT-KO mice served as baseline controls. Data are shown as 
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activity during pneumococcal infection. NE-AAT complex formation was examined by using BALF of  S. 
pneumoniae–challenged AAT-KO mice receiving hAAT therapy or vehicle. As shown in Figure 6A, BALF 
collected from PBS-treated, S. pneumoniae–challenged AAT-KO mice incubated or not with NE in vitro 
did not show any AAT protein in Western blots (Figure 6A, lanes 1, 3). However, AAT protein was easily 
detectable in BALF of  S. pneumoniae–challenged AAT-KO mice treated with hAAT (lane 2), with 2 bands of  
different molecular size representing native AAT (lower band in lane 2) or NE-AAT complex (upper band 
in lane 2). Furthermore, the addition of  purified NE to BALF of  hAAT-augmented, S. pneumoniae–infected 
AAT-KO mice led to a nearly complete shift of  the aforementioned lower band of  native AAT to the protein 
band representing NE-AAT complexes (upper band in lane 4), clearly confirming the anti-NE activity of  the 
hAAT preparation. As a control, blotting of  hAAT protein gave a single band (lane 5), whereas hAAT pre-
incubated with NE generated 2 AAT-specific bands of  lower and higher molecular size representing native 
hAAT and NE-complexed hAAT, respectively (both lane 6). As expected, NE protein alone gave no signal 
in AAT-specific Western blotting (lane 7).
To confirm further that hAAT preserves anti-NE activity during pneumococcal pneumonia in AAT-
KO mice, BALF of  PBS-treated or hAAT-augmented, S. pneumoniae–challenged AAT-KO mice were 
subjected to kinetic NE activity assay. As shown in Figure 6B, BALF of  PBS-treated and S. pneumoniae–
infected AAT-KO mice exhibited easily detectable NE activity similar to that of  purified NE (serving as 
positive control). However, AAT purified from BALF of  hAAT-augmented, S. pneumoniae–challenged 
AAT-KO mice showed substantially less NE activity (Figure 6B). Hence, exogenously applied hAAT 
seems to be fully active during pneumococcal infection of  AAT-KO mice and is not inactivated by any 
putative infection-evoked reactive intermediates.
Attenuated antibacterial immunity in AAT-KO mice is due to NE-dependent degradation of  alveolar collectins sur-
factant protein A and D. Previous studies in patients with cystic fibrosis revealed that elastolytic activities in BAL 
fluids were inversely related to levels of  respiratory opsonins (30). Therefore, we next questioned whether 
NE might contribute to the attenuated antibacterial responses in S. pneumoniae–challenged AAT-KO mice by 
functionally depleting alveolar collectins surfactant protein A (SP-A) and SP-D. As shown in Figure 7, WT 
and AAT-KO mice exhibited similar levels of  alveolar SP-A and SP-D under baseline conditions (Figure 7, 
A and B, lanes 1, 2). In response to S. pneumoniae challenge, SP-A and SP-D proteins (both monomeric 42 
kDa and higher-order oligomeric protein bands (>75 kDa) in Figure 7B were easily detectable in BALF of  
WT mice, whereas both collectins were nearly completely degraded in BALF of  S. pneumoniae–challenged 
AAT-KO mice (both monomeric and oligomeric forms) (Figure 7, A and B, lanes 5, 6). Importantly, such 
depletion of  SP-A and SP-D could be completely inhibited by hAAT treatment of  S. pneumoniae–infected 
AAT-KO mice (Figure 7, A and B, lanes 7, 8).
We next aimed to clarify whether NE was indeed responsible for the observed SP-A/SP-D degradation 
in S. pneumoniae–challenged AAT-KO mice. Therefore, we examined the effect of  increasing concentrations 
of  purified NE on SP-D protein levels in BALF of  S. pneumoniae–challenged WT mice. As shown in Figure 
7C, we found that NE even at a concentration of  0.5 μg was sufficient to degrade SP-D protein into even 
smaller SP-D fragments (lane 3), while addition of  2 μg NE per sample completely degraded SP-D protein 
in BAL fluids of  S. pneumoniae–challenged WT mice (Figure 7C, lane 5). Importantly, preincubation of  
purified NE with hAAT in vitro (in order to complex and thus inactivate the protease prior to addition to 
BALF) completely protected BALF-derived SP-D proteins from the degradation (Figure 7C, lanes 6 to 9).
In the next set of  experiments, we examined whether purified NE would also degrade recombinant 
SP-D (rSP-D) protein in vitro. Of  note, addition of  just 0.5 μg purified NE per sample was sufficient to 
nearly completely degrade rSP-D protein in vitro (Figure 7D, lane 3 and 4), similar to the observation 
made in BAL fluids of  WT mice (Figure 7C).
We next hypothesized that if  NE is the culprit to degrade collectins SP-A and SP-D both in vivo and 
in vitro, NE-deficient mice should be protected from NE-mediated depletion of  alveolar collectins. Indeed, 
as shown in Figure 7E, SP-D protein was easily detectable in BALF of  S. pneumoniae–challenged NE-KO 
mice, with similar band intensities observed in S. pneumoniae–challenged WT mice (compare lanes 1, 2 in 
Figure 7E with lanes 3, 4 in Figure 7B), and a similar pattern of  SP-D was observed in AAT-treated, S. 
mean ± SD of n = 4–9 mice per time point and treatment group. (H–L) TNF-α, IL-1β, IL-6, CXCL1, and desmosine levels in BAL fluids of mice at days 2–3 postinfec-
tion. Data are shown as mean ± SD of n = 7–9 mice per time point and treatment group. *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 compared with vehicle-treated mice, +P 
≤ 0.05 compared with day 2 (Mann-Whitney U test, log-rank test). All data are representative of 2 independent experiments.
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Figure 4. Effect of AAT augmentation therapy with active or oxidized AAT on outcome in S. pneumoniae–infected AAT-KO and NE-KO mice. AAT-KO 
mice were treated with Respreeza (gray bars), vehicle (white bars), or oxidized Respreeza (black bars) i.p. at 6 hours prior to pneumococcal infection and at 
days 0 and 1 postinfection. (A and B) Bacterial loads in BALF (A) and lung tissue (B) were determined at 48 hours postinfection. Data are shown as mean ± 
SD of n = 6–8 mice per time point and treatment group and are representative of 2 independently performed experiments. NE-KO mice were treated with 
Respreeza (gray bars) or vehicle (white bars) i.p. starting 24 hours postinfection with S. pneumoniae. (C and D) Bacterial loads in BALF (C) and lung tissue 
(D) were determined at 48 hours postinfection. Data are shown as mean ± SD of n = 6–9 mice per time point and treatment group and are representative 
of 2 independently performed experiments. (E–L) TNF-α, IL-1β, IL-6, and CXCL1 cytokine levels in BAL fluids and lung homogenate supernatants of NE-KO 
mice at day 2 postinfection, as indicated. Data are shown as mean ± SD of n = 8–11 mice per time point and treatment group and are representative of 2 
independently performed experiments. **P ≤ 0.01, compared with vehicle-treated mice. (Mann-Whitney U test, log-rank test.)
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pneumoniae–challenged NE-KO mice. These data clearly support our hypothesis that neutrophil-derived NE 
is the major protease mediating degradation of  lung collectins in S. pneumoniae–infected AAT-KO mice.
Using a sensitive ELISA for quantification of  alveolar SP-D, we found that SP-D levels significantly 
increased in BALF of  WT mice upon pneumococcal challenge compared with untreated WT mice, 
whereas upon S. pneumoniae challenge BALF SP-D levels of  AAT-KO mice increased only weakly and 
nonsignificantly (Figure 7F). Importantly, the infection-driven rise in SP-D levels could be significantly 
restored in BALF of  AAT-KO mice upon therapy with hAAT (Figure 7F).
Finally, we hypothesized that if  NE-mediated degradation of  lung collectins contributes to the dis-
turbed antibacterial immunity in AAT-KO mice, blockade of  NE with specific inhibitors should reverse 
this process. To this end, AAT-KO mice were treated with the highly specific NE inhibitor Sivelestat twice 
Figure 5. Phagocytosis, killing, and burst induction in S. pneumoniae-infected alveolar macrophages and bone mar-
row-derived neutrophils of WT and AAT-KO mice. (A–D) Phagocytosis capacity of resident alveolar macrophages (rAMs) 
and bone marrow–derived neutrophils (BM-PMNs) infected with S. pneumoniae was analyzed at 30 minutes postinfec-
tion of cells with S. pneumoniae at a multiplicity of infection (MOI) of 25. The killing capacity of rAMs and BM-PMNs 
infected with S. pneumoniae in the absence or presence of AAT was determined at 90 minutes postinfection. (E and F) 
Formation of reactive oxygen species (burst) in highly purified BM-PMNs induced by S. pneumoniae (MOI 5) (E) or zymo-
san (F). Data are representative of 2 independent experiments with n = 4 mice per time point and treatment group.
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daily subsequent to S. pneumoniae infection. As shown in Figure 7G, therapeutic application of  Sivelestat 
protected SP-D from NE-dependent degradation in BALF of  S. pneumoniae–infected AAT-KO mice, rela-
tive to vehicle-treated, S. pneumoniae–challenged AAT-KO mice completely lacking alveolar SP-D protein 
and when compared with S. pneumoniae–challenged WT mice (compare lanes 3, 4 in Figure 7G with lanes 
3, 4 in Figure 7B). Again, quantification of  SP-D levels by ELISA confirmed significantly increased SP-D 
levels in BALF of  S. pneumoniae–infected AAT-KO mice after treatment with Sivelestat, reaching a similar 
order of  magnitude as observed in AAT-treated, S. pneumoniae–infected AAT-KO mice (compare Figure 
7H with Figure 7F). Most importantly, we found that treatment with Sivelestat inhibited exaggerated NE 
activity, and thus loss of  alveolar collectins led to significantly decreased bacterial loads both in BAL fluids 
and lungs of  S. pneumoniae–infected AAT-KO mice (Figure 7, I and J).
Collectively, our data show that NE is the major culprit in degrading SP-A and SP-D in S. pneumoniae–
challenged AAT-KO mice, thereby disturbing lung protective immunity in AAT-deficient mice. The latter 
can be restored by both hAAT augmentation therapy and using synthetic NE inhibitors.
Discussion
In the current study, we evaluated the impact of  AATD on lung protective immunity against S. pneumo-
niae in mice in the absence or presence of  AAT augmentation therapy. To reflect the clinical situation of  
patients with inherited AATD, we used recently generated AAT-KO mice lacking all 5 mouse serpin A1 
paralogues, thus leading to complete AAT protein deficiency. AAT-KO mice were used at the age of  8–14 
Figure 6. NE-AAT complex formation in BAL fluids of S. pneumoniae-challenged AAT-KO mice receiving augmenta-
tion therapy. (A) AAT (lane 2, lower protein band) and NE-AAT complex formation (lanes 2 and 4, upper protein band) 
detected in BAL fluids of AAT-augmented AAT-KO mice but not in PBS-treated AAT-KO mice (lanes 1 and 3). As a con-
trol, blotting of hAAT protein only gave rise to 1 single band in Western blot analysis (lane 5), and hAAT preincubated 
with purified NE in vitro resulted in 2 AAT-specific bands representing noncomplexed, native hAAT and NE-complexed 
hAAT (lane 6). NE protein alone gave no signal in AAT-specific Western blotting (lane 7). Lanes 1 to 7 were run on the 
same gel but were noncontiguous. (B) BAL fluids of S. pneumoniae–challenged AAT-KO mice receiving AAT augmenta-
tion therapy as compared with vehicle were subjected to kinetic NE activity assay. Purified elastase served as positive 
control. Data are representative of 3 independently performed experiments.
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weeks while spontaneously developing lung emphysema only at advanced age of  more than 35 weeks (25). 
Based on the data generated from this model, we show that AATD is detrimental to mice infected with S. 
pneumoniae but could be rescued upon treatment with plasma-purified hAAT.
Patients with AATD receive augmentation therapy primarily to slow down emphysema progression. To 
this end, patients with AATD typically receive standard doses of  60 mg/kg/wk intravenously to restore at 
least 50% of normal AAT serum levels (approximately 11 μM) (10). Although calculated standard doses may 
be sufficient to reverse the biochemical AAT defects in stable patients (10), little is known about serum AAT 
levels needed in case of  microbial challenge where AAT turnover kinetics might be increased, as observed in 
the current study. Actually, previous studies showed that patients with AATD are more likely to suffer from 
pulmonary infections, which could be ameliorated by AAT therapy. A recent study by Balbi et al. reported 
that augmentation therapy in AATD patients with COPD significantly reduced the percentage of  gram-pos-
itive and -negative bacteria (H. influenzae, S. pneumoniae) compared with controls (23). In addition, in a (sub-
jective) questionnaire-based study by Lieberman, patients with ZZ AATD reported significantly fewer lung 
infections per year under augmentation therapy compared with those subjects with the same phenotype who 
were not receiving this therapy (31). Moreover, cystic fibrosis (CF) patients with deficient variants of  AAT 
demonstrated an earlier carriage of  P. aeruginosa, which was correlated with an earlier onset of  P. aeruginosa 
lung infection (32). In contrast, CF patients receiving AAT therapy demonstrated significantly lower bacterial 
loads of  P. aeruginosa (33). Together, these studies strongly support the view that AATD is associated with 
attenuated antibacterial immunity and that augmentation therapy contributes to the reduced incidence and 
severity of  lung bacterial colonization and/or infection in AATD but also in non-AATD CF patients.
Lower elastolytic activities were reported in BALF of  patients with AATD under standard augmenta-
tion therapy (19). In our experimental settings, bacterial infection significantly decreased plasma AAT lev-
els in mice by approximately 25% (Figure 1), allowing us to predict that bacterial infection in patients with 
AATD would result in a transient drop of  AAT plasma levels. Thus, the currently applied AAT therapy 
dosing regimen may be sufficient to diminish bacterial burden in patients with AATD but may be too low 
to adequately neutralize increasing NE activity due to the peripheral neutrophilia developing in response 
to acute bacterial infection. Based on a previous study (19) and our report, clinically relevant arguments 
to increase AAT augmentation therapy to more physiological levels may be (a) to facilitate an improved 
inhibition of  ECM-degrading NE activity in the bronchoalveolar space of  AATD patients (19) and (b) to 
better protect AATD patients against increased AAT turnover expectedly developing upon lung bacterial 
infections, which would also lower the risk of  emphysema progression/exacerbation.
Various aspects may explain the observed infection-induced decrease of  plasma AAT levels in mice. 
First, both elevated AAT consumption caused by peripheral neutrophilia and/or leakage of  AAT into 
the alveolar space may have contributed to the observed drop in AAT protein levels. Moreover, an active 
trans-endo-/epithelial transport of  AAT has also been described (34, 35). Third, it is conceivable that septic 
liver injury developing in response to invasive pneumococcal disease may also result in decreased AAT 
serum levels, although this aspect is unlikely to be relevant in the current model of  focal pneumonia.
AAT-KO mice were found to succumb to pneumococcal lung infection by day 2 postinfection. We 
found a markedly higher NE activity in BAL-derived neutrophils of  S. pneumoniae–infected AAT-KO 
as compared with WT mice. This finding is in line with the lack of  antiprotease activity of  AAT in the 
KO but not in the WT mice, which actually responded to pneumococcal lung infection with signifi-
cantly increased bronchoalveolar release of  AAT. NE is a highly potent serine protease able to degrade 
lung ECM, such as elastin, and may facilitate proinflammatory cytokine activation in the inflammatory 
microenvironment (12, 13, 29). In the current study, we show that levels of  desmosine, an amino acid 
Figure 7. NE degrades collectins SP-A and SP-D in the lungs of AAT-deficient mice. (A and B) SP-A (A) and SP-D (B) proteins in BAL fluids of untreated or 
S. pneumoniae–infected WT mice (lanes 3, 4) as compared with AAT-KO mice (lanes 5, 6) as compared with AAT-augmented AAT-KO mice (lanes 7, 8) on 
day 2 postinfection (F, fragment). (C) Dose-dependent degradation of SP-D by NE in BAL fluids of S. pneumoniae–challenged WT mice (lanes 2–5), while 
preincubation of NE with AAT fully protected SP-D protein from degradation (lanes 6–9). (D) Incubation of recombinant SP-D protein with NE leads to 
degradation of recombinant SP-D protein. (E) SP-D protein in BAL fluids of S. pneumoniae–infected NE-KO mice with or without AAT augmentation therapy. 
(F) Quantification of SP-D protein levels in BAL fluids of mice of the respective treatment groups by ELISA, as indicated. (G–J) Effect of treatment of S. 
pneumoniae-challenged AAT-KO mice with selective NE inhibitor Sivelestat on SP-D levels in BAL fluids (G and H) and bacterial loads in BAL fluids (I) and 
lung tissue (J) of AAT-KO mice relative to vehicle treatment, as indicated. (D and E) Lanes 1 to 4 were run on the same gel but were noncontiguous. Data are 
shown as mean ± SD of n = 6–10 mice per time point and treatment group and are representative of 2 independently performed experiments. *P ≤ 0.05, **P 
≤ 0.01, ***P ≤ 0.001, compared with vehicle-treated mice. (Mann-Whitney U test.)
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released from elastin upon its degradation, increased substantially in BALF of  S. pneumoniae–challenged 
AAT-KO relative to WT mice. These data demonstrate that NE actually triggers ECM degradation in the 
lungs of  mice in the absence of  AAT, and this process is profoundly inhibited upon AAT augmentation. 
Furthermore, analysis of  the proinflammatory cytokines TNF-α, IL-1β, IL-6, and CXCL1 illustrated 
the effect of  AAT augmentation therapy on lung inflammatory responses after bacterial challenge in 
nonaugmented as compared with augmented AAT-KO mice. Actually, these data show that augmenta-
tion therapy of  S. pneumoniae–infected AAT-KO mice improved survival by effectively diminishing lung 
bacterial loads and the release of  proinflammatory cytokines, which — in addition to the bacterial infec-
tion — may significantly contribute to lung damage. Together, these data clearly show an important role 
of  alveolar AAT in blocking NE-mediated lung tissue damage in mice. Our findings are consistent with 
similar observations in AATD patients subjected to AAT augmentation therapy (19), thus supporting the 
clinical relevance of  the current AAT-KO mouse model of  AATD.
To explain the observed differences in antibacterial responses discriminating S. pneumoniae–challenged 
WT from AAT-KO mice, we examined the bacterial phagocytosis, killing, and burst capacity of  alveolar 
macrophages and neutrophils from WT and AAT-KO mice in vitro. However, we did not note any signif-
icant differences between groups. Hence, it seems very unlikely that the observed differences in bacterial 
loads between WT and AAT-KO mice are due to principal differences in the phagocytosis/killing or respi-
ratory burst capacity of  professional phagocytes between these 2 experimental groups.
However, based on the observation that AAT-KO mice exhibited a drastically increased proteolytic bur-
den in their lungs upon pneumococcal challenge, which was largely blocked by AAT therapy along with a 
significant reduction in lung bacterial loads, we hypothesized that NE was the major culprit to disturb lung 
antibacterial immunity in S. pneumoniae–challenged AAT KO. Previous studies in patients with CF showed 
that NE is capable of  disturbing lung antibacterial immunity at different levels, including degradation of  the 
opsonophagocytically important collectins SP-A and -D (36, 37), as well as degradation of  pathogen-specif-
ic immunoglobulins (30). According to our understanding, pathogen-evoked protective antibody responses 
were very unlikely to develop so quickly in our employed acute lung infection model. However, the hydro-
philic lung surfactant proteins SP-A and SP-D are well-known to serve as opsonophagocytically relevant 
collectins to orchestrate lung host defense against various lung-tropic pathogens, including S. pneumoniae, 
based on in vitro studies and genetically engineered animal models (38–43). In the current study, we provide 
evidence that NE is responsible for the observed degradation of  SP-A and SP-D in S. pneumoniae–infected 
AAT-KO mice, which is accompanied by decreased antibacterial defense. Of note, in addition to the cur-
rently reported degradation of  lung collectins by neutrophil-derived NE, peroxynitrite may also affect the 
binding activity of  SP-A and SP-D, due to its strong nitrating and oxidizing effects (44). Other studies report-
ed neutrophil-derived myeloperoxidase-dependent inactivation of  SP-D in vivo (45). Actually, our findings 
provide a potentially novel and hitherto unrecognized molecular mechanism by which inherited AATD 
affects lung antibacterial immunity, besides its well-known effect on lung emphysema progression in patients 
with AATD, and how this defect can be corrected by augmentation therapy.
Chronic lung diseases like CF or COPD are characterized by a vicious circle of  bronchoalveolar recruit-
ment of  neutrophils with subsequent excess release of  NE culminating in end-stage emphysematous lung 
injury. At the same time, both CF and COPD patients have increased susceptibility to opportunistic bacterial 
infections, which at least in CF is causally responsible for excess lung neutrophil recruitment. A previous 
study suggested particularly NE to be responsible for mediating lung collectin depletion in BAL fluids of  CF 
patients (46), although this study did not relate these findings to antibacterial immune defects. As mentioned 
before, a recent study by Balbi et al. (23) reported that AAT treatment significantly reduced total bacterial 
loads, including S. pneumoniae, in sputum samples of  COPD patients when compared with untreated COPD 
patients. Therefore, when taking together previous studies and our work, it appears reasonable that the suc-
cess of  AAT augmentation therapy of  (mostly neutrophil-dominated) chronic lung diseases should not only 
rely on long-term inhibition of  emphysema development or progression but also should aim at inhibition of  
NE-dependent depletion of  SP-A and SP-D in order to avoid defective antibacterial responses.
Collectively, we propose the following model: in WT mice, NE released into the alveolar airspace 
upon infection (at least partially) becomes complexed with AAT, thereby limiting both NE-driven degra-
dation of  lung ECM components as well as lung collectins SP-A and SP-D. In contrast, in AAT-KO mice, 
S. pneumoniae challenge triggers increased alveolar neutrophil accumulation and thus NE liberation that 
is not inhibited by AAT. This consequently triggers increased NE-dependent lung ECM degradation, as 
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determined by increased alveolar desmosine levels, and even further triggers a nearly complete function-
al depletion of  SP-A and SP-D collectins within the alveolar compartment, thereby profoundly affect-
ing lung bacterial pathogen elimination. Upon AAT augmentation therapy or application of  NE-specific 
inhibitors, excessive neutrophil-derived NE activity is blocked, thus inhibiting ECM degradation and deg-
radation of  collectins, thereby facilitating a normalized bacterial pathogen elimination process similar to 
that observed in S. pneumoniae–challenged, AAT-sufficient WT mice.
As such, the current study expands our understanding of  the impact of  augmentation therapy on 
lung protective immunity in patients with inherited AATD and how this therapy might be combined in 
the future with more cost-efficient NE-specific inhibitor therapies. Importantly, however, we believe that 
these data may also be critically important to other neutrophil-dominated lung diseases where continuous 
recruitment of  neutrophils is associated with defects in lung antibacterial immunity, including (but not 
limited to) CF, COPD, as well as bronchiectasis.
Methods
Animals. WT mice (C57BL/6) were purchased from Janvier Lab (Le Genest-Saint-Isle, France). AAT-KO 
mice lacking all of  the 5 serpin A1 a-e paralogues expressed in mice were generated as described recently 
(25). NE-KO mice were purchased from The Jackson Laboratory (Bar Harbor, Maine, USA) (47). Age- and 
sex-matched mice were used for experiments at 8 to 14 weeks of  age.
Reagents. Respreeza (plasma-purified human AAT) was purchased from CSL Behring (Marburg, 
Germany). NE-specific inhibitor Sivelestat (48) was purchased from MilliporeSigma (St. Louis, Missou-
ri, USA). Anti-CD45 PE-Cy7 (clone 30-F11) and anti-Ly6G V450 (clone 1A8) were purchased from BD 
Biosciences (Heidelberg, Germany). Mouse neutrophil isolation kit was purchased from MACS, Miltenyi 
Biotec (Bergisch Gladbach, Germany). For Western blot analysis, polyclonal rabbit anti-mouse SP-A 
antibody (catalog ABIN3043205) was purchased from antibodies-online (Aachen, Germany). Monoclo-
nal rabbit anti-mouse SP-D antibody (clone EPR21774-143) and monoclonal rabbit anti-hAAT antibody 
(clone EPR17087-50) were purchased from Abcam (Cambridge, United Kingdom). rSP-D was purchased 
from antibodies-online. Antigen specificity of  the employed anti-hAAT antibody, or anti-mouse SP-A and 
anti-mouse SP-D antibody, was confirmed by liquid chromatography-mass spectrometry at the Proteomics 
Core facility of  Hannover Medical School (data not shown).
Culture and quantification of  S. pneumoniae. For details, see Supplemental Methods.
Growth kinetics of  S. pneumoniae in the presence of  AAT. For details, see Supplemental Methods.
Infection of  mice with S. pneumoniae. Infection of  mice with capsular group 19F S. pneumoniae was done 
as recently described (49, 50). For further information, see Supplemental Methods.
Determination of  bacterial loads in BAL fluids and lung homogenates. For details, see Supplemental Methods.
Oxidation of  human purified AAT. Oxidization of  native hAAT was achieved as described previously (27, 
28, 51, 52).
Treatment groups. Five treatment groups were established: WT mice were mock infected (PBS) or were 
infected with S. pneumoniae as described above, and endogenous AAT levels were determined in plasma and 
BALF at different time points postinfection.
The role of  AAT deletion on evolving pneumococcal pneumonia was examined in AAT-KO mice and 
WT mice (serving as controls), which were infected orotracheally with S. pneumoniae, and disease progres-
sion was monitored during an observation period of  6 days.
The effect of  AAT augmentation on antibacterial immunity in AAT-KO mice was studied by treating 
AAT-KO mice i.p. with either purified hAAT (2 mg/mouse twice daily) or PBS (vehicle control) at 6 hours 
prior to infection with S. pneumoniae and subsequent determination of  CFU in BALF and lung tissue as 
well as assessment of  survival and lung histopathology.
To exclude potential immunomodulatory effects of  AAT on lung protective immunity against S. pneu-
moniae in mice, AAT-KO mice were treated i.p. with PBS, purified hAAT (exhibiting NE-inhibitory and 
putative immunomodulatory activity) (2 mg/mouse twice daily), or oxidized hAAT lacking NE-inhibitory 
activity (2 mg/mouse twice daily) (27, 28, 51, 53) followed by infection with S. pneumoniae. In additional 
experiments, NE-deficient mice were treated with human purified AAT or PBS starting at 24 hours post-
infection followed by determination of  bacterial loads and cytokine responses in BALF and lung tissue.
To analyze the effect of  selective NE inhibition on lung antibacterial immunity in AAT-KO mice, mice 
were treated i.p. with Sivelestat (2 mg/mouse twice daily) or saline (vehicle control), starting immediately 
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after infection with S. pneumoniae. Bacterial loads in BALF and lung tissue, as well as SP-D levels in BALF of  
S. pneumoniae–challenged AAT-KO mice of  both treatment groups, were determined on day 1 postinfection.
Phagocytosis and bacterial killing assay. Phagocytosis and bacterial killing assays were performed as 
recently described (54–56). For further details, see Supplemental Methods.
Analysis of  respiratory burst induction in BM-PMNs. For details, see Supplemental Methods.
Isolation of  AAT protein from BAL fluids of  S. pneumoniae–infected mice. AAT protein was purified from 
BALF of  mice by affinity chromatography using AAT-specific Alpha-1 Antitrypsin Select matrix (Cytiva, 
Marlborough, Massachusetts, USA) according to the manufacturer’s recommendations. In brief, pooled 
BAL samples were diluted 1:3 with binding buffer (20 mM Tris/HCl 150 mM NaCl pH 7.4) and loaded 
onto Alpha-1 Antitrypsin Select columns. AAT was eluted in elution buffer (2 M MgCl2 in 20 mM Tris/
HCl pH 7.6), and AAT concentrations were measured via NanoDrop 1000 Spectrophotometer (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA). AAT-containing fractions were concentrated and buffer 
was changed to PBS using 10 kDa cutoff  centricons (MilliporeSigma, Burlington, Massachusetts, USA).
Western blot analysis. Plasma and BALF samples of  untreated or S. pneumoniae–infected WT and 
AAT-KO mice treated with PBS or hAAT were subjected to SDS-PAGE under reducing conditions fol-
lowed by Western blot analysis of  hAAT protein or collectins SP-A and SP-D, according to previously 
published protocols (49, 54). Exogenously applied hAAT was detected in mice using anti-hAAT anti-
body. Collectins SP-A and SP-D were detected using rabbit anti-mouse anti-SP-A antibody or rabbit anti-
mouse anti-SP-D antibody. Protein bands were detected by enhanced chemiluminescence signals (ECL 
Plus; Cytiva, Buckinghamshire, United Kingdom) using a Vilber Lourmat Chemismart 5000 analyzer 
and Bio1D software (Vilber Lourmat, Eberhardzell, Germany).
For NE-dependent SP-D degradation experiments in vitro, indicated amounts of  purified human NE 
were incubated with BALF of  S. pneumoniae–infected WT mice or with recombinant murine SP-D protein 
(antibodies-online) for 15 minutes at 37°C. Inhibition of  NE was done by incubating indicated amounts 
of  purified NE with hAAT at a molar ratio of  1:2 for 1 hour at 37°C before adding NE-AAT complexes to 
the respective samples. Reactions were stopped by adding 4× SDS sample buffer (Bio-Rad Laboratories, 
Irvine, California, USA) with β-mercaptoethanol and heating at 95°C for 5 minutes.
Detection of  NE complex formation with hAAT purified from BALF of  hAAT-augmented mice was 
achieved by preincubating BALF-derived hAAT with either PBS or NE (5 ng/mL; MilliporeSigma, St. 
Louis, Missouri, USA) for 1 hour at 37°C. The reaction was stopped by adding equal volumes of  2× SDS 
sample buffer without β-mercaptoethanol and heating at 95°C for 3 minutes. Samples were then subjected 
to SDS-PAGE under nonreducing conditions followed by Western blot analysis of  NE-hAAT complexes. 
Immune complexes were detected using a polyclonal rabbit anti-hAAT-specific antibody (Dako, Glostrup, 
Denmark) using ECL-enhanced chemiluminescence analysis.
Gelatin-based zymography of  total proteolytic activity in BAL fluids of  S. pneumoniae–infected AAT-KO mice. 
The total proteolytic activity in BAL fluids of  S. pneumoniae–infected AAT-KO mice treated with PBS, 
native AAT, or oxidized AAT was determined by gelatin-based Novex Zymogram Plus gels (Thermo 
Fisher Scientific, Waltham, Massachusetts, USA). Briefly, BAL samples were diluted according to man-
ufacturer’s instructions, equal volumes of  5 μL per well were loaded onto the gelatin-containing gel, and 
electrophoresis was performed as recommended by the manufacturer. Subsequently, gels were stained 
with Coomassie blue. Those regions of  the gel, where the gelatin was degraded by active BAL fluid pro-
teases, do appear as white bands on a black background.
NE activity assay. The effect of  hAAT augmentation therapy on neutrophil-dependent elastase activ-
ity in S. pneumoniae–infected AAT-KO mice was examined by NE enzyme activity assay, according to 
previously published protocols (57–61). Briefly, BAL cells of  S. pneumoniae–infected mice containing 
more than 90% neutrophils or BM-PMNs were centrifuged for 9 minutes at 430g at 4°C followed by 
lysis (5 minutes) of  red blood cells using hypotonic lysis solution (AppliChem, Darmstadt, Germany) 
and subsequent washing in PBS. Neutrophil pellets were then washed once in ice-cold HBSS, and 2 × 
106 neutrophils per mouse were then transferred into small reaction tubes and centrifuged for 10 minutes 
at 600g at 4°C. Resulting neutrophil pellets were resuspended in 50 μL Tris buffer (0.2 M Tris, 0.15 M 
NaCl, 0.02 M CaCl2, pH 8.5) containing 20 μg/mL gentamicin (MilliporeSigma, St. Louis, Missouri, 
USA). For determination of  NE activity, a standard curve ranging from 0 to 150 ng of  catalytically active 
human NE/μL was established using commercially available human NE (MilliporeSigma, Burlington, 
Massachusetts, USA). NE-specific substrate MeO-Suc-Ala-Ala-Pro-Val-pNA (MilliporeSigma, St. Louis, 
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Missouri, USA) was added to respective samples and standards in 96-well plates, which were then incu-
bated for 1 hour at 37°C followed by measurements of  NE activities expressed as release of  4-nitroaniline 
using a microplate reader operated at OD410 nm (VersaMax, Molecular Devices, Biberach, Germany). 
BM-PMNs from WT and AAT-KO mice served as baseline controls, and alveolar recruited neutrophils 
from S. pneumoniae–infected, hAAT-treated NE-KO mice as well as neutrophils from S. pneumoniae–
infected mice preincubated with hAAT in vitro served as negative controls.
For kinetic NE activity measurements, samples were transferred to 96-well plates, purified elas-
tase (stock solution 20 μg/mL, MilliporeSigma, St. Louis, Missouri, USA) and 0.1 M Tris buffer (pH 
8.0) were added, and reaction mixtures were incubated at 37°C for 5 minutes. Following incubation, 
NE-specific substrate N-Succinyl-Ala-Ala-Ala-p-nitroanilide (MilliporeSigma, St. Louis, Missouri, 
USA) was added to the reaction mixtures. The absorbance was determined by using a microplate reader 
operated at OD 405 nm in a kinetic mode.
Lung histopathology. For details, see Supplemental Methods.
Quantification of  neutrophils in BAL and lung tissue. For details, see Supplemental Methods.
ELISA. Murine AAT levels were measured in plasma and BALF of  S. pneumoniae–infected mice using 
a commercially available mouse alpha-1 antitrypsin ELISA Kit (Crystal Chem Europe, Zaandam, Nether-
lands). Exogenously applied hAAT was measured in plasma and BALF of  AAT-KO mice using a human 
Serpin A1 DuoSet ELISA lacking cross-reactivity for murine Serpin A1 (R&D Systems, Bio-Techne, 
Wiesbaden, Germany), according to the manufacturer’s instructions. TNF-α, IL-1β, IL-6, and CXCL1 
cytokines were measured in BALF and lung homogenate supernatants of  S. pneumoniae–infected AAT-
KO mice and NE-KO mice receiving AAT augmentation therapy or vehicle using commercially available 
murine Quantikine ELISA Kits (R&D Systems, Bio-Techne). Mouse SP-D and desmosine levels were 
measured in BALF of  untreated and S. pneumoniae–infected WT and AAT-KO mice using commercially 
available mouse SP-D (Abcam, Cambridge, United Kingdom) and mouse desmosine ELISA (Cusabio, 
Texas, USA) according to the manufacturers’ instructions.
Statistics. Statistical analysis was performed with GraphPad Prism software. Data are shown as 
mean ± SD values. Statistically significant differences between groups were analyzed by Mann-Whitney 
U test, and differences in survival between groups were analyzed using log-rank test. P values of  less 
than 0.05 were considered statistically significant.
Study approval. All animal experiments corresponded to the European guideline 2010/63/EU and were 
authorized by the Lower Saxony State Office for Consumer Protection and Food Safety, Wardenburg, Germany.
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